Literature DB >> 29796854

Breast cancer metastasis through the lympho-vascular system.

S David Nathanson1, David Krag2, Henry M Kuerer3, Lisa A Newman4, Markus Brown5, Dontscho Kerjaschki6, Ethel R Pereira7, Timothy P Padera7.   

Abstract

Breast cancer metastasizes through the lymphovascular system to the regional lymph nodes in the axilla and to both visceral and non-visceral sites. Renewed interest in the route by which tumor cells gain access to blood and lymphatic capillaries are the subject of research at mechanical, anatomic, pathologic, genetic, epidemiologic and molecular levels. Two papers presented at the 7th International Symposium on Cancer Metastasis in San Francisco showed tumor cells entering the systemic circulation through the sentinel lymph node. This information challenges the current paradigm where clinicians believe that access is gained through intra- and peri-tumoral blood vessels and that metastasis to axillary lymph nodes is an interesting epi-phenomenon. The sentinel lymph node era has changed the modern surgical approach to the axilla and the basis of this change is summarized in this paper. A new approach to the management of axillary metastases after systemic therapy relies on determining whether there is a complete pathologic response; if no tumor is found in the previously biopsied node, a complete axillary lymph node dissection may be avoided. African American women seem to inherit a trait from West African ancestors and tend to develop more lethal types of breast cancer. These tumors may have a molecular machinery that enhances their ability to metastasize to visceral sites and future research may unearth the mechanisms for this phenomenon.

Entities:  

Keywords:  Axilla; Breast cancer sentinel lymph nodes; Metastasis; Racial disparities; Targeted dissection

Mesh:

Year:  2018        PMID: 29796854     DOI: 10.1007/s10585-018-9902-1

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  81 in total

1.  The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer.

Authors:  Rosalinda Alvarado; Min Yi; Huong Le-Petross; Michael Gilcrease; Elizabeth A Mittendorf; Isabelle Bedrosian; Rosa F Hwang; Abigail S Caudle; Gildy V Babiera; Jeri S Akins; Henry M Kuerer; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2012-07-07       Impact factor: 5.344

2.  Improving the Accuracy of Axillary Lymph Node Surgery in Breast Cancer with Ultrasound-Guided Wire Localization of Biopsy Proven Metastatic Lymph Nodes.

Authors:  Donna Plecha; Shiyu Bai; Helen Patterson; Cheryl Thompson; Robert Shenk
Journal:  Ann Surg Oncol       Date:  2015-03-27       Impact factor: 5.344

3.  Proceedings: Tumor angiogenesis factor.

Authors:  J Folkman
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

4.  Axillary Staging After Neoadjuvant Chemotherapy for Breast Cancer: A Pilot Study Combining Sentinel Lymph Node Biopsy with Radioactive Seed Localization of Pre-treatment Positive Axillary Lymph Nodes.

Authors:  Emilia J Diego; Priscilla F McAuliffe; Atilla Soran; Kandace P McGuire; Ronald R Johnson; Marguerite Bonaventura; Gretchen M Ahrendt
Journal:  Ann Surg Oncol       Date:  2016-01-04       Impact factor: 5.344

5.  Breast cancer survival in African-American women by hormone receptor subtypes.

Authors:  Tomi Akinyemiju; Justin Xavier Moore; Sean F Altekruse
Journal:  Breast Cancer Res Treat       Date:  2015-08-07       Impact factor: 4.872

6.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

7.  Expanding Implementation of ACOSOG Z0011 in Surgeon Practice.

Authors:  Anna Weiss; Elizabeth A Mittendorf; Sarah M DeSnyder; Rosa F Hwang; Vivian Bea; Isabelle Bedrosian; Karen Hoffman; Beatriz Adrade; Aysegul A Sahin; Henry M Kuerer; Kelly K Hunt; Abigail S Caudle
Journal:  Clin Breast Cancer       Date:  2017-10-13       Impact factor: 3.225

8.  Features of triple-negative breast cancer: Analysis of 38,813 cases from the national cancer database.

Authors:  Magdalena L Plasilova; Brandon Hayse; Brigid K Killelea; Nina R Horowitz; Anees B Chagpar; Donald R Lannin
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

9.  Opportunities for improving triple-negative breast cancer outcomes: results of a population-based study.

Authors:  Elisabetta Rapiti; Kim Pinaud; Pierre O Chappuis; Valeria Viassolo; Aurélie Ayme; Isabelle Neyroud-Caspar; Massimo Usel; Christine Bouchardy
Journal:  Cancer Med       Date:  2017-02-17       Impact factor: 4.452

10.  Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy.

Authors:  Robert Lindner; Catherine Sullivan; Onyinye Offor; Kimberly Lezon-Geyda; Kyle Halligan; Neal Fischbach; Mansi Shah; Veerle Bossuyt; Vincent Schulz; David P Tuck; Lyndsay N Harris
Journal:  PLoS One       Date:  2013-11-18       Impact factor: 3.240

View more
  14 in total

Review 1.  Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

Authors:  Jesse Yu; Qingxin Mu; Millie Fung; Xiaolin Xu; Linxi Zhu; Rodney J Y Ho
Journal:  Pharmacol Ther       Date:  2022-01-06       Impact factor: 13.400

Review 2.  Future perspectives: cancer metastases.

Authors:  Stanley P Leong; Jonathan S Zager
Journal:  Clin Exp Metastasis       Date:  2018-07-23       Impact factor: 5.150

Review 3.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

4.  Early SUVmax is the best predictor of axillary lymph node metastasis in stage III breast cancers.

Authors:  Jiangong Zhang; Xun Shi; Yong Xiao; Chao Ma; Gang Cao; Yongbo Liu; Yonggang Li
Journal:  Quant Imaging Med Surg       Date:  2021-05

5.  Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling.

Authors:  Gardiyawasam Kalpana; Christopher Figy; Miranda Yeung; Kam C Yeung
Journal:  Sci Rep       Date:  2019-11-08       Impact factor: 4.379

6.  Nomogram for Predicting Lymph Node Involvement in Triple-Negative Breast Cancer.

Authors:  Xiang Cui; Hao Zhu; Jisheng Huang
Journal:  Front Oncol       Date:  2020-12-04       Impact factor: 6.244

7.  Integrative Bioinformatics Study of Tangeretin Potential Targets for Preventing Metastatic Breast Cancer.

Authors:  Adam Hermawan; Herwandhani Putri; Naufa Hanif; Muthi Ikawati
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

8.  MDA-MB-231 Breast Cancer Cells and Their CSC Population Migrate Towards Low Oxygen in a Microfluidic Gradient Device.

Authors:  Jelle J F Sleeboom; Jaap M J den Toonder; Cecilia M Sahlgren
Journal:  Int J Mol Sci       Date:  2018-10-06       Impact factor: 5.923

9.  Hematogenous Dissemination of Breast Cancer Cells From Lymph Nodes Is Mediated by Tumor MicroEnvironment of Metastasis Doorways.

Authors:  Anouchka Coste; George S Karagiannis; Yarong Wang; Emily A Xue; Yu Lin; Mihaela Skobe; Joan G Jones; Maja H Oktay; John S Condeelis; David Entenberg
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

Review 10.  Lymphatic Endothelial Markers and Tumor Lymphangiogenesis Assessment in Human Breast Cancer.

Authors:  Jia-Mei Chen; Bo Luo; Ru Ma; Xi-Xi Luo; Yong-Shun Chen; Yan Li
Journal:  Diagnostics (Basel)       Date:  2021-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.